Skip to main content
Top
Published in:

18-12-2023 | Insulins | Review Article

Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications

Author: Takayoshi Sasako

Published in: Diabetology International | Issue 1/2024

Login to get access

Abstract

It is important to prevent not only diabetic complications but also diabetic comorbidities in diabetes care. We have elucidated multifaceted insulin action in various tissues mainly by means of model mice, and it was revealed that insulin regulates endoplasmic reticulum (ER) stress response during feeding, whereas ER stress ‘response failure’ contributes to the development of steatohepatitis, one of the major diabetic comorbidities. Insulin regulates gluconeogenesis not only in the liver but also in the proximal tubules of the kidney, which is also suppressed by reabsorbed glucose in the latter. In skeletal muscle, another important insulin-targeted tissue, impaired insulin/IGF-1 signaling leads not only to sarcopenia, an aging-related disease, but also to bone loss and shorter longevity. Aging is regulated by adipokines as well, and it is deemed to be accelerated by ‘imbalanced adipokines’ in combination with genetic background of progeria. Moreover, we reported effects of intensive multifactorial intervention on diabetic complications and mortality in patients with type 2 diabetes in a large-scale clinical trial, the J-DOIT3, followed by reports of subsequent sub-analyses of renal events and fracture events. Various approaches to elucidate the mechanisms underlying the development of diabetes and how it should be treated are expected to help us improve diabetes management.
Literature
1.
go back to reference The Japan Diabetes Society Group. Treatment guide for diabetes 2022–2023. Tokyo: Bunkodo; 2022. The Japan Diabetes Society Group. Treatment guide for diabetes 2022–2023. Tokyo: Bunkodo; 2022.
2.
go back to reference Kubota N, Kubota T, Itoh S, et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 2008;8(1):49–64.PubMedCrossRef Kubota N, Kubota T, Itoh S, et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 2008;8(1):49–64.PubMedCrossRef
3.
go back to reference Kadowaki T, Ueki K, Yamauchi T, Kubota N. SnapShot: insulin signaling pathways. Cell. 2012;148(3):624,e1.PubMedCrossRef Kadowaki T, Ueki K, Yamauchi T, Kubota N. SnapShot: insulin signaling pathways. Cell. 2012;148(3):624,e1.PubMedCrossRef
6.
go back to reference Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat Med. 2010;16(4):429–37.PubMedPubMedCentralCrossRef Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat Med. 2010;16(4):429–37.PubMedPubMedCentralCrossRef
7.
go back to reference Winnay JN, Boucher J, Mori MA, Ueki K, Kahn CR. A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med. 2010;16(4):438–45.PubMedPubMedCentralCrossRef Winnay JN, Boucher J, Mori MA, Ueki K, Kahn CR. A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med. 2010;16(4):438–45.PubMedPubMedCentralCrossRef
8.
go back to reference Fukuda S, Sumii M, Masuda Y, et al. Murine and human SDF2L1 is an endoplasmic reticulum stress-inducible gene and encodes a new member of the Pmt/rt protein family. Biochem Biophys Res Commun. 2001;280(1):407–14.PubMedCrossRef Fukuda S, Sumii M, Masuda Y, et al. Murine and human SDF2L1 is an endoplasmic reticulum stress-inducible gene and encodes a new member of the Pmt/rt protein family. Biochem Biophys Res Commun. 2001;280(1):407–14.PubMedCrossRef
9.
go back to reference Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–5.PubMedCrossRef Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–5.PubMedCrossRef
10.
go back to reference Sasako T, Ueki K. ER stress response failure and steatohepatitis comorbid with diabetes. In: Psychology and patho-physiological outcomes of eating. IntechOpen Ltd; 2021. p. 69–83. Sasako T, Ueki K. ER stress response failure and steatohepatitis comorbid with diabetes. In: Psychology and patho-physiological outcomes of eating. IntechOpen Ltd; 2021. p. 69–83.
11.
go back to reference Tateishi R, Matsumura T, Okanoue T, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021;56(3):261–73.PubMedPubMedCentralCrossRef Tateishi R, Matsumura T, Okanoue T, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021;56(3):261–73.PubMedPubMedCentralCrossRef
12.
go back to reference Soeda K, Sasako T, Enooku K, et al. Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. Nat Commun. 2023;14(1):6584.PubMedPubMedCentralCrossRef Soeda K, Sasako T, Enooku K, et al. Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. Nat Commun. 2023;14(1):6584.PubMedPubMedCentralCrossRef
13.
go back to reference Bhattarai KR, Chaudhary M, Kim HR, Chae HJ. Endoplasmic reticulum (ER) stress response failure in diseases. Trends Cell Biol. 2020;30(9):672–5.PubMedCrossRef Bhattarai KR, Chaudhary M, Kim HR, Chae HJ. Endoplasmic reticulum (ER) stress response failure in diseases. Trends Cell Biol. 2020;30(9):672–5.PubMedCrossRef
14.
go back to reference Yagil C, Varadi-Levi R, Ifrach C, Yagil Y. Dysregulated UPR and ER stress related to a mutation in the Sdf2l1 gene are involved in the pathophysiology of diet-induced diabetes in the Cohen diabetic RAT. Int J Mol Sci. 2023;24(2):1355.PubMedPubMedCentralCrossRef Yagil C, Varadi-Levi R, Ifrach C, Yagil Y. Dysregulated UPR and ER stress related to a mutation in the Sdf2l1 gene are involved in the pathophysiology of diet-induced diabetes in the Cohen diabetic RAT. Int J Mol Sci. 2023;24(2):1355.PubMedPubMedCentralCrossRef
15.
go back to reference Sazonovs A, Stevens CR, Venkataraman GR, et al. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Nat Genet. 2022;54(9):1275–83.PubMedPubMedCentralCrossRef Sazonovs A, Stevens CR, Venkataraman GR, et al. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Nat Genet. 2022;54(9):1275–83.PubMedPubMedCentralCrossRef
16.
go back to reference Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;120:S1-6.CrossRef Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;120:S1-6.CrossRef
17.
go back to reference Butlen D, Vadrot S, Roseau S, Morel F. Insulin receptors along the rat nephron: [125I] insulin binding in microdissected glomeruli and tubules. Pflugers Arch. 1988;412(6):604–12.PubMedCrossRef Butlen D, Vadrot S, Roseau S, Morel F. Insulin receptors along the rat nephron: [125I] insulin binding in microdissected glomeruli and tubules. Pflugers Arch. 1988;412(6):604–12.PubMedCrossRef
18.
go back to reference Tiwari S, Singh RS, Li L, et al. Deletion of the insulin receptor in the proximal tubule promotes hyperglycemia. J Am Soc Nephrol. 2013;24(8):1209–14.PubMedPubMedCentralCrossRef Tiwari S, Singh RS, Li L, et al. Deletion of the insulin receptor in the proximal tubule promotes hyperglycemia. J Am Soc Nephrol. 2013;24(8):1209–14.PubMedPubMedCentralCrossRef
19.
go back to reference Sasaki M, Sasako T, Kubota N, et al. Dual regulation of gluconeogenesis by insulin and glucose in the proximal tubules of the kidney. Diabetes. 2017;66(9):2339–50.PubMedCrossRef Sasaki M, Sasako T, Kubota N, et al. Dual regulation of gluconeogenesis by insulin and glucose in the proximal tubules of the kidney. Diabetes. 2017;66(9):2339–50.PubMedCrossRef
20.
go back to reference Rubera I, Poujeol C, Bertin G, et al. Specific Cre/Lox recombination in the mouse proximal tubule. J Am Soc Nephrol. 2004;15(8):2050–6.PubMedCrossRef Rubera I, Poujeol C, Bertin G, et al. Specific Cre/Lox recombination in the mouse proximal tubule. J Am Soc Nephrol. 2004;15(8):2050–6.PubMedCrossRef
21.
22.
go back to reference Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation. 2020;141(25):2095–105.PubMedCrossRef Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation. 2020;141(25):2095–105.PubMedCrossRef
23.
go back to reference Liu H, Sridhar VS, Lovblom LE, et al. Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes. Kidney Int Rep. 2021;6(8):2095–104.PubMedPubMedCentralCrossRef Liu H, Sridhar VS, Lovblom LE, et al. Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes. Kidney Int Rep. 2021;6(8):2095–104.PubMedPubMedCentralCrossRef
24.
go back to reference Sasako T, Tanaka T, Yamauchi T. Adaptive response as a potential key link between SGLT2 inhibition and renoprotection. Kidney Int Rep. 2021;6(8):2022–4.PubMedPubMedCentralCrossRef Sasako T, Tanaka T, Yamauchi T. Adaptive response as a potential key link between SGLT2 inhibition and renoprotection. Kidney Int Rep. 2021;6(8):2022–4.PubMedPubMedCentralCrossRef
25.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentralCrossRef Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentralCrossRef
26.
go back to reference Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.PubMedCrossRef Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.PubMedCrossRef
27.
go back to reference Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–7.PubMedCrossRef Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–7.PubMedCrossRef
28.
go back to reference Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183–92.PubMedPubMedCentralCrossRef Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183–92.PubMedPubMedCentralCrossRef
29.
go back to reference Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34(11):2381–6.PubMedPubMedCentralCrossRef Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34(11):2381–6.PubMedPubMedCentralCrossRef
30.
31.
go back to reference Jaiswal N, Gavin M, Loro E, et al. AKT controls protein synthesis and oxidative metabolism via combined mTORC1 and FOXO1 signalling to govern muscle physiology. J Cachexia Sarcopenia Muscle. 2022;13(1):495–514.PubMedCrossRef Jaiswal N, Gavin M, Loro E, et al. AKT controls protein synthesis and oxidative metabolism via combined mTORC1 and FOXO1 signalling to govern muscle physiology. J Cachexia Sarcopenia Muscle. 2022;13(1):495–514.PubMedCrossRef
32.
go back to reference Sasako T, Umehara T, Soeda K, et al. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. Nat Commun. 2022;13(1):5655.PubMedPubMedCentralCrossRef Sasako T, Umehara T, Soeda K, et al. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. Nat Commun. 2022;13(1):5655.PubMedPubMedCentralCrossRef
33.
go back to reference Kirk B, Al Saedi A, Duque G. Osteosarcopenia: a case of geroscience. Aging Med (Milton). 2019;2(3):147–56.PubMedCrossRef Kirk B, Al Saedi A, Duque G. Osteosarcopenia: a case of geroscience. Aging Med (Milton). 2019;2(3):147–56.PubMedCrossRef
35.
go back to reference Tian J, Chung HK, Moon JS, et al. Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice. J Cachexia Sarcopenia Muscle. 2022;13(3):1785–99.PubMedPubMedCentralCrossRef Tian J, Chung HK, Moon JS, et al. Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice. J Cachexia Sarcopenia Muscle. 2022;13(3):1785–99.PubMedPubMedCentralCrossRef
36.
go back to reference Hosoi T, Yakabe M, Sasakawa H, et al. Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor. Proc Natl Acad Sci USA. 2023;120(4): e2218032120.PubMedPubMedCentralCrossRef Hosoi T, Yakabe M, Sasakawa H, et al. Sarcopenia phenotype and impaired muscle function in male mice with fast-twitch muscle-specific knockout of the androgen receptor. Proc Natl Acad Sci USA. 2023;120(4): e2218032120.PubMedPubMedCentralCrossRef
38.
go back to reference Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185–96.PubMedCrossRef Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185–96.PubMedCrossRef
39.
go back to reference Sasako T, Kadowaki H, Fujiwara T, et al. Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy-associated progeroid syndrome due to an LMNA variant: a case report. J Diabetes Investig. 2022;13(9):1636–8.PubMedPubMedCentralCrossRef Sasako T, Kadowaki H, Fujiwara T, et al. Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophy-associated progeroid syndrome due to an LMNA variant: a case report. J Diabetes Investig. 2022;13(9):1636–8.PubMedPubMedCentralCrossRef
40.
go back to reference Hosoe J, Miya F, Kadowaki H, et al. Clinical usefulness of multigene screening with phenotype-driven bioinformatics analysis for the diagnosis of patients with monogenic diabetes or severe insulin resistance. Diabetes Res Clin Pract. 2020;169: 108461.PubMedCrossRef Hosoe J, Miya F, Kadowaki H, et al. Clinical usefulness of multigene screening with phenotype-driven bioinformatics analysis for the diagnosis of patients with monogenic diabetes or severe insulin resistance. Diabetes Res Clin Pract. 2020;169: 108461.PubMedCrossRef
41.
go back to reference Hussain I, Patni N, Ueda M, et al. A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation. J Clin Endocrinol Metab. 2018;103(3):1005–14.PubMedCrossRef Hussain I, Patni N, Ueda M, et al. A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation. J Clin Endocrinol Metab. 2018;103(3):1005–14.PubMedCrossRef
43.
go back to reference Seki Y, Yamada T, Kiyosue A, et al. Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1. J Cardiol Cases. 2022;26(4):248–51.PubMedPubMedCentralCrossRef Seki Y, Yamada T, Kiyosue A, et al. Asymptomatic myocardial infarction in a patient with myotonic dystrophy type 1. J Cardiol Cases. 2022;26(4):248–51.PubMedPubMedCentralCrossRef
44.
go back to reference Nakagawa-Nagahama Y, Igarashi M, Miura M, Sasako T, Yamauchi T. A case of variant hemoglobin Hb Hoshida [β 43 Glu (GAG) → Gln (CAG) ] diagnosed at the onset of acute-onset type 1 diabetes mellitus. J Japan Diab Soc. 2022;65(9):505–11. Nakagawa-Nagahama Y, Igarashi M, Miura M, Sasako T, Yamauchi T. A case of variant hemoglobin Hb Hoshida [β 43 Glu (GAG) → Gln (CAG) ] diagnosed at the onset of acute-onset type 1 diabetes mellitus. J Japan Diab Soc. 2022;65(9):505–11.
45.
go back to reference Sasako T, Yamauchi T. Clinical trials in participants with type 2 diabetes undertaken in Japan. J Japan Diab Soc. 2022;65(10):518–21. Sasako T, Yamauchi T. Clinical trials in participants with type 2 diabetes undertaken in Japan. J Japan Diab Soc. 2022;65(10):518–21.
46.
48.
go back to reference Ueki K, Sasako T, Kato M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care. 2016;4(1): e000123.PubMedPubMedCentralCrossRef Ueki K, Sasako T, Kato M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care. 2016;4(1): e000123.PubMedPubMedCentralCrossRef
49.
go back to reference Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951–64.PubMedCrossRef Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951–64.PubMedCrossRef
51.
go back to reference Sone H, Tanaka S, Iimuro S, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010;53(3):419–28.PubMedPubMedCentralCrossRef Sone H, Tanaka S, Iimuro S, et al. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010;53(3):419–28.PubMedPubMedCentralCrossRef
52.
go back to reference Griffin SJ, Rutten G, Khunti K, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(12):925–37.PubMedCrossRef Griffin SJ, Rutten G, Khunti K, et al. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(12):925–37.PubMedCrossRef
53.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
54.
go back to reference Sasako T, Kadowaki T, Ueki K. ADDITION-Europe: the first decade and beyond. Lancet Diabetes Endocrinol. 2019;7(12):891–3.PubMedCrossRef Sasako T, Kadowaki T, Ueki K. ADDITION-Europe: the first decade and beyond. Lancet Diabetes Endocrinol. 2019;7(12):891–3.PubMedCrossRef
55.
go back to reference Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–66.PubMedCrossRef Ueki K, Sasako T, Okazaki Y, et al. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney Int. 2021;99(1):256–66.PubMedCrossRef
56.
go back to reference Sasako T, Yamauchi T. Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. Kidney Int. 2022;101(2):222–4.PubMedCrossRef Sasako T, Yamauchi T. Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. Kidney Int. 2022;101(2):222–4.PubMedCrossRef
57.
go back to reference Sasako T, Ueki K, Miyake K, et al. Effect of a multifactorial intervention on fracture in patients with type 2 diabetes: subanalysis of the J-DOIT3 study. J Clin Endocrinol Metab. 2021;106(5):e2116–28.PubMedPubMedCentralCrossRef Sasako T, Ueki K, Miyake K, et al. Effect of a multifactorial intervention on fracture in patients with type 2 diabetes: subanalysis of the J-DOIT3 study. J Clin Endocrinol Metab. 2021;106(5):e2116–28.PubMedPubMedCentralCrossRef
58.
go back to reference Chan JCN. How can we optimise diabetes care in real-world practice? Lancet Diabetes Endocrinol. 2017;5(12):927–9.PubMedCrossRef Chan JCN. How can we optimise diabetes care in real-world practice? Lancet Diabetes Endocrinol. 2017;5(12):927–9.PubMedCrossRef
59.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.PubMedCrossRef
60.
go back to reference Sasako T, Yamauchi T, Ueki K. Intensified multifactorial intervention in patients with type 2 diabetes mellitus. Diabetes Metab J. 2023;47(2):185–97.PubMedPubMedCentralCrossRef Sasako T, Yamauchi T, Ueki K. Intensified multifactorial intervention in patients with type 2 diabetes mellitus. Diabetes Metab J. 2023;47(2):185–97.PubMedPubMedCentralCrossRef
Metadata
Title
Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications
Author
Takayoshi Sasako
Publication date
18-12-2023
Publisher
Springer Nature Singapore
Published in
Diabetology International / Issue 1/2024
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-023-00677-3

Other articles of this Issue 1/2024

Diabetology International 1/2024 Go to the issue

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more